$ABBV Recent News AbbVie's stock rallies 1.8%, leads

New Post Public Reply Private Reply Replies (0) Message Board

Dec 24, 2014 at 1:21 PM

$ABBV Recent News

AbbVie's stock rallies 1.8%, leads S&P 500 gainers 9:34 a.m. Today - Tomi Kilgore
Health-care sector taking a broad beating as pricing fears grow 2:39 p.m. Dec. 23, 2014 - Tomi Kilgore
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
S&P 500, Dow industrials close at records 4:41 p.m. Dec. 22, 2014 - Sara Sjolin
Stock market may wish investors a wary Christmas 8:19 a.m. Dec. 22, 2014 - Shawn Langlois
Express Scripts picks AbbVie over Gilead for hepatitis C drug 7:45 a.m. Dec. 22, 2014 - Joseph Walker
FDA approves AbbVie’s hepatitis treatment 3:33 p.m. Dec. 19, 2014 - Peter Loftus
AbbVie's stock gains 0.8% after FDA approval of hepatitis C treatment 3:21 p.m. Dec. 19, 2014 - Tomi Kilgore
Which stocks the billionaires are buying — and selling 1:32 p.m. Dec. 12, 2014 - The Trading Deck
Paulson takes stake in Abbvie, adds to Shire holdings 6:46 p.m. Nov. 14, 2014 - MarketWatch
Obama considering Lazard banker for Treasury post 4:20 p.m. Nov. 12, 2014 - Victoria McGrane
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
S&P 500, Dow close at record levels 4:16 p.m. Oct. 31, 2014 - Barbara Kollmeyer
Apple rallies to record high; LinkedIn jumps 11:05 a.m. Oct. 31, 2014 - Sue Chang
AbbVie stock up 3.6% at $63.38 9:32 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie shares up 4% in premarket trade 8:52 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie raises outlook as profit, sales beat 8:26 a.m. Oct. 31, 2014 - MarketWatch.com
AbbVie shares up 2% as profit, sales beat estimates 8:00 a.m. Oct. 31, 2014 - Ciara Linnane
AbbVie prior FY EPS outlook was $3.06 to $3.16 7:54 a.m. Oct. 31, 2014 - Ciara Linnane

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog 9:48 a.m. Today - Zacks.com
Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers 9:33 a.m. Today - Seeking Alpha
Gilead Feels The Heat Of Competition 7:59 a.m. Today - Seeking Alpha
Dow Tops 18000 7:50 p.m. Dec. 23, 2014 - The Wall Street Journal Interactive Edition
Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog 4:50 p.m. Dec. 23, 2014 - Zacks.com
AbbVie Puts The Hurt On Gilead Sciences, Closes Exclusive Deal With Express Scripts 4:41 p.m. Dec. 23, 2014 - Seeking Alpha
Dow Reaches Record Close as Santa Claus Rally Hits Day 5 4:04 p.m. Dec. 23, 2014 - TheStreet.com
Investors Should Stay Long Stocks as Market Continues Hitting Highs 3:01 p.m. Dec. 23, 2014 - TheStreet.com
Dow, S&P 500 Near Session Highs After GDP Growth Smashes Expectations 2:25 p.m. Dec. 23, 2014 - TheStreet.com
Gilead Sciences Plunges for Second Day In A Row: What Wall Street's Saying 1:48 p.m. Dec. 23, 2014 - TheStreet.com
Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs to Watch - ETF News And Commentary 12:02 p.m. Dec. 23, 2014 - Zacks.com
Dow Industrials Top 18,000 but Biopharma Stocks Drag Nasdaq Lower 11:29 a.m. Dec. 23, 2014 - TheStreet.com
AbbVie (ABBV): Stock With Unusual Social Activity 11:21 a.m. Dec. 23, 2014 - TheStreet.com
Analysts Predict Big Value Trap for Gilead Investors 11:20 a.m. Dec. 23, 2014 - 247WallSt.com
Dow Crosses 18,000 for First Time on GDP Surge 11:06 a.m. Dec. 23, 2014 - InvestorPlace.com
Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer 11:01 a.m. Dec. 23, 2014 - TheStreet.com
Enanta Is The Big Winner In The Hepatitis C War Between Abbvie And Gilead 8:47 a.m. Dec. 23, 2014 - Seeking Alpha
AbbVie HCV combo med cleared in Canada 7:58 a.m. Dec. 23, 2014 - Seeking Alpha
AbbVie Competes On Price 7:58 a.m. Dec. 23, 2014 - Seeking Alpha
Gilead Sciences: Buy On The Drop? 7:35 a.m. Dec. 23, 2014 - Seeking Alpha

Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference 8:00 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie 9:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need 7:00 a.m. Dec. 22, 2014 - PR Newswire - PRF
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines 9:10 a.m. Dec. 12, 2014 - PR Newswire - PRF
AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting 8:15 p.m. Dec. 7, 2014 - PR Newswire - PRF
Gardy & Notis LLP Issues Notice Of The Filing Of A Securities Class Action Against AbbVie And Its Chief Executive Officer 4:00 p.m. Nov. 26, 2014 - PR Newswire - PRF
CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe 8:00 a.m. Nov. 21, 2014 - PR Newswire - PRF
AbbVie to Present at Jefferies 2014 Global Healthcare Conference 7:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 4:48 p.m. Nov. 14, 2014 - PR Newswire - PRF
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 9:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 8:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Infinity Reports Third Quarter 2014 Financial Results and Provides Company Update 4:01 p.m. Nov. 6, 2014 - BusinessWire - BZX
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries 8:50 a.m. Nov. 6, 2014 - PR Newswire - PRF
ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty 8:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
AbbVie to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
ABBVIE INC. ALERT -- Andrews & Springer LLC is Investigating AbbVie Inc. for Potential Securities Fraud and Breach of Fiduciary Duty 8:09 a.m. Nov. 3, 2014 - GlobeNewswire
Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) 7:05 a.m. Nov. 3, 2014 - GlobeNewswire
CMK Select Recognized as Women's Business Enterprise 10:45 a.m. Oct. 31, 2014 - Marketwired
AbbVie Reports Third-Quarter 2014 Financial Results 7:49 a.m. Oct. 31, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amgen's Board Gains Restaurateur Gibbs Amid Strategic Shift

A Heavyweight Joiner Shakes Up Amgen's Ranks You can almost feel the ground shake when Amgen, a tech giant in biotech, ropes in a high-profile namesake from outside its usual league. David W. Gibbs, the former CEO of Yum! Brands, is now staking his claim at Amgen as a member of its Board of Directors. Effective immediately, Gibbs isn’t just a filler; he's diving...

AI's Rise: Worth Watching for M&A Strategy Insights

AI: The Hot Topic You Can't Ignore AI's rocking the boat like SEO did back in the day, folks. The Digital WOW is giving M&A Source® members a real scoop with their exclusive webinar, zeroing in on AI's potential seismic shifts in mergers and acquisitions. This should make any investor sit up and pay attention. AI's not just a tech buzzword anymore. It's like a strong cup...

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Texas Instruments' $2B Notes Fuel Acquisition Ambitions

Pushing Forward with Big Dollars Texas Instruments is setting the stage with an ambitious move by pricing $2.0 billion in investment-grade notes, preparing to shake things up with an acquisition. It's not every day you see a player like TXN dipping into the bond market with such confidence, yet here we are. Four series of senior unsecured notes are slated for issuance on...

E-Filing: Why Ditching IRS Paper Forms Matters Now

Tax Filing Today: The Old vs. The New Listen up, tax-filing warriors. Tackling that IRS Form 941 deadline isn’t just another play in the small business game—it’s crunch time. November 2, 2026, isn’t waiting around for excuses. Luckily, Halfpricesoft.com just chucked you a lifeline with their updated ezPaycheck platform. Swap that mountain of mangled paper forms...

Custom Concrete: Crafting the Perfect Poolside Paradise

Concrete: The Unsung Hero of Your Pool's Success You know, everyone always raves about that sparkling pool, but let's be real—it's the concrete holding the whole gig together. James White from White's Pools in Loganville, GA, drops some knowledge in a recent HelloNation piece about the unsung hero of backyard oases: custom concrete. Yeah, it's not sexy, but when you're...

Bertram Capital Backs MCE's Expansive Growth Vision

A Strategic Move for Bertram Capital Right on the heels of seasoned market moves, Bertram Capital has thrown its support behind Motion & Control Enterprises (MCE). This isn't just another portfolio addition; it's a calculated step into the complex world of industrial distribution, partnering with a company renowned for its prowess in engineered solutions. If you've ever...

Energy Fuels Secures Key Financing for Donald Project

Donald Project: A Step Closer to Reality Look, when those rare earths start moving, the entire market gets a whiff of promise. Energy Fuels' Donald Rare Earth and Mineral Sands Project in Australia is gearing up for real action with a fresh funding nod. Export Finance Australia and the National Reconstruction Fund Corporation have conditionally greenlit up to A$180...

Skechers Facing Class Action: Investors Urged to Act

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Brennan Takes a Swing: Barrasso Endorsement in Hand

Brennan Shakes Up Wyoming Politics You don’t need a crystal ball to see the chess game unfolding in Wyoming's political landscape. Shannon Brennan's bid for the House seat in Teton County's District 23 got a heavy artillery boost today. She’s landed the endorsement of Senator John Barrasso, none other than the Senate Majority Whip and a formidable player in the Senate...